摘要
目的:观察苏黄泻浊丸对单侧输尿管梗阻(UUO)大鼠肾功能、尿微量白蛋白及可溶性CD146表达的影响。方法:采用大鼠单侧输尿管梗阻方法(UUO)制备肾间质纤维化模型,实验分为正常组、假手术组、模型组、尿毒清组及苏黄泻浊丸组,每组14只,各组给予生理盐水或相应药物灌胃,连续28 d。HE染色观察大鼠肾组织病理变化,检测各组大鼠肾功能(SCr、BUN)、尿微量白蛋白及血、尿sCD146变化。结果:HE染色显示,尿毒清颗粒组和苏黄泻浊丸组肾小管、间质病理学改变较模型组病变程度明显减轻。模型组大鼠肾功能、尿微量白蛋白及血、尿sCD146与正常组相比较差异明显(P<0.05),给药组上述指标与模型组相比较差异明显(P<0.05);除尿sCD146检测苏黄泻浊丸组与尿毒清组间比较无统计学差异(P>0.05)外,其余指标苏黄泻浊丸组与尿毒清组比较均有明显差异(P<0.05)。结论:苏黄泻浊丸能够改善UUO模型大鼠肾功能,减少尿微量白蛋白排泄,降低sCD146表达,延缓UUO模型大鼠肾间质纤维化进程。
Objective:To observe the effects of Suhuang Xiezhuo Pill on renal function,urine minimal albumin and soluble CD146 expression in unilateral ureter obstruction(UUO)rats.Methods:UUO were used to cope renal interstitial fibrosis models,experiment was divided into normal,sham operation,model,positive(Niaoduqing)and Suhuang Xiezhuo Pill groups,each contained 14 rats,every group was given saline or corresponding medicine for 28 days,pathological changes of rats’kidney tissue were observed by HE staining,blood SCr,BUN and urine minimal albumin of each group rats were determined,blood and urine sCD146levels were determined by ELISA.Results:HE staining results showed that the renal tube and interstate pathological changes of positive and Suhuang Xiezhuo Pill groups were significantly reduced to compare with the model group.To compare with normal group,blood SCr,BUN,urine minimal albumin and blood,urine sCD146 levels of model group were raised significantly(P<0.05),all above indexes in positive and Suhuang Xiezhuo Pill groups were lowered,there were significant differences between medication groups and model group(P<0.05);blood SCr,BUN,urine minimal albumin and blood sCD146 levels in Suhuang Xiezhuo Pill groups were significantly lower than those in positive group(P<0.05),the difference between the two groups on urine sCD146 level was no significant(P>0.05).Conclusion:Suhuang Xiezhuo Pill can improve renal function of UUO rats,reduce the urine minimal albumin excretion,decrease sCD146 expression,delay the process of renal interstitial fibrosis of UUO rats.
作者
于卓
陈明
刘子洋
张佩青
YU Zhuo;CHEN Ming;LIU Ziyang;ZHANG Peiqing(Heilongjiang Academy of Chinese Medicine Sciences,Harbin,Heilongjiang 150036)
出处
《中国中医药科技》
CAS
2021年第6期873-875,共3页
Chinese Journal of Traditional Medical Science and Technology
基金
黑龙江省中医药科研项目(ZHY18-028)。